TT01001

TT01001 is a selective and orally active mitoNEET agonist and a monoamine oxidase B (MAO-B) inhibitor (IC50 = 8.84 μM) . TT01001 does not activate PPARγ but interacts with MitoNEET. TT01001 attenuates oxidative stress and neuronal apoptosis by preventing mitoNEET-mediated mitochondrial dysfunction. TT01001 improves type II diabetes and ameliorates mitochondrial function of mice. TT01001 can used for the studies of type II diabetes and neurological disorders [1][2][3].

Product Specifications

CAS Number

[1022367-69-6]

Product Name Alternative

NSC144303

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Mitochondrial Metabolism; Monoamine Oxidase; Reactive Oxygen Species (ROS)

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; Neuronal Signaling; NF-κB

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/tt01001.html

Purity

99.38

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(OCC)N1CCC(CC1)NC(NC2=CC(Cl)=CC(Cl)=C2)=S

Molecular Formula

C15H19Cl2N3O2S

Molecular Weight

376.30

Precautions

H302, H315, H319, H335

References & Citations

[1]Takehiro Takahashi, et al. A novel MitoNEET ligand, TT01001, improves diabetes and ameliorates mitochondrial function in db/db mice. J Pharmacol Exp Ther. 2015, 352, 2.|[2]Shi G, et al. TT01001 attenuates oxidative stress and neuronal apoptosis by preventing mitoNEET-mediated mitochondrial dysfunction after subarachnoid hemorrhage in rats. Neuroreport. 2020;31 (11) :845-850. |[3]Barbosa Belchior M, et al. Synthesis and evaluation of enzyme inhibition by novel TT01001 derivatives as monoamine oxidase B inhibitors. Bioorg Med Chem Lett. 2025 Mar 1;117:130045.